{"schema_version":"1.0","type":"article","title":"Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.md","lang":"zh-Hant","date":"2026-06-14","publish_at":"2026-06-14T00:54:00.739Z","updated_at":"2026-06-14","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"2026 年，全球最受矚目的 Biotech 之一，毫無疑問是 Revolution Medicines。這家公司站在一個極難、也極誘人的位置：RAS-addicted cancers。","key_points":[],"facts":[],"sections":["Revolution Medicines 的千億神話：會研發還不夠，會融資才撐得過新藥長跑","01｜Revolution 是燒錢黑洞，也是融資高手","02｜真正厲害的不是募到錢，而是每次都在催化後募錢","03｜EQRx 反向併購：熊市裡最聰明的現金補給","04｜Royalty Pharma 交易：不是缺錢才融資，而是為了保留獨立商業化選擇權","05｜📈 Revolution 的真正能力，是把臨床 momentum 轉成資本 momentum","06｜台灣生技最缺的，往往不是題材，而是融資節奏","07｜會融資，不是投機，而是對病人和股東負責","08｜Revolution 的啟示：Biotech 最後比的是「科學 × 資本 × 執行」的複利","結語｜Revolution Medicines 的神話，不只是 RAS，而是把資本變成研發速度"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/revolution-medicines-experimental-cancer-pill-helps-improve-survival-late-stage-2026-04-13/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"\"Revolution Medicines' experimental cancer pill boosts survival in late-stage study","source":"Reuters\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress - BioSpace","source":"","date":"","url":""},{"title":"https://www.biospace.com/press-releases/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress","source":"","date":"","url":"https://www.biospace.com/press-releases/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress"},{"title":"www.biospace.com","source":"","date":"","url":""},{"title":"\"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress - BioSpace\"","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"ir.revmed.com","source":"","date":"","url":""},{"title":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit"},{"title":"ir.revmed.com","source":"","date":"","url":""},{"title":"\"Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer","source":"Revolution Medicines\"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"ir.revmed.com","source":"","date":"","url":""},{"title":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-closing-upsized-public-offering-2/","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-closing-upsized-public-offering-2/"},{"title":"ir.revmed.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"ir.revmed.com","source":"","date":"","url":""},{"title":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-inc-announces-proposed-offerings-common","source":"","date":"","url":"https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-inc-announces-proposed-offerings-common"},{"title":"ir.revmed.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 1）","url":"https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-01.webp"},{"alt":"Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 2）","url":"https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-02.png"},{"alt":"Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 3）","url":"https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revolution-medicines/cover.svg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-14）。Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑。https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-14-revolution-medicines-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}